Century Therapeutics, Inc. (NASDAQ:IPSC - Get Free Report) SVP Douglas Carr sold 7,043 shares of the stock in a transaction that occurred on Thursday, March 12th. The stock was sold at an average price of $2.55, for a total transaction of $17,959.65. Following the transaction, the senior vice president directly owned 507,261 shares of the company's stock, valued at $1,293,515.55. The trade was a 1.37% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Douglas Carr also recently made the following trade(s):

• On Tuesday, February 3rd, Douglas Carr sold 323 shares of Century Therapeutics stock. The shares were sold at an average price of $1.82, for a total value of $587.86.

Century Therapeutics Stock Performance

Shares of IPSC traded up $0.09 during midday trading on Monday, hitting $2.43. 815,753 shares of the stock were exchanged, compared to its average volume of 1,847,081. Century Therapeutics, Inc. has a 52-week low of $0.34 and a 52-week high of $3.04. The stock has a fifty day simple moving average of $2.08 and a 200 day simple moving average of $1.12. The firm has a market cap of $212.39 million, a P/E ratio of -17.36 and a beta of 1.70.

Century Therapeutics (NASDAQ:IPSC - Get Free Report) last posted its quarterly earnings data on Thursday, March 12th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.04. As a group, equities research analysts forecast that Century Therapeutics, Inc. will post -1.61 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on IPSC shares. Zacks Research lowered shares of Century Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Thursday. Piper Sandler increased their target price on shares of Century Therapeutics from $2.00 to $4.00 and gave the stock an "overweight" rating in a report on Tuesday, January 20th. Leerink Partners set a $2.00 price target on shares of Century Therapeutics and gave the stock a "market perform" rating in a research note on Friday. Wall Street Zen raised Century Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, March 7th. Finally, TD Cowen began coverage on Century Therapeutics in a research note on Wednesday, February 25th. They issued a "buy" rating on the stock. Five analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $3.80.

View Our Latest Analysis on IPSC

Institutional Investors Weigh In On Century Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Bank of America Corp DE boosted its position in shares of Century Therapeutics by 109.1% during the 4th quarter. Bank of America Corp DE now owns 66,043 shares of the company's stock worth $67,000 after acquiring an additional 34,466 shares in the last quarter. AQR Capital Management LLC raised its position in shares of Century Therapeutics by 358.9% during the 1st quarter. AQR Capital Management LLC now owns 111,079 shares of the company's stock worth $53,000 after acquiring an additional 86,875 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in Century Therapeutics by 26.9% during the first quarter. Goldman Sachs Group Inc. now owns 179,635 shares of the company's stock worth $86,000 after purchasing an additional 38,052 shares during the last quarter. Acadian Asset Management LLC boosted its holdings in Century Therapeutics by 101.2% in the first quarter. Acadian Asset Management LLC now owns 284,229 shares of the company's stock valued at $133,000 after purchasing an additional 142,953 shares in the last quarter. Finally, Prudential Financial Inc. acquired a new position in Century Therapeutics in the second quarter valued at approximately $25,000. 50.20% of the stock is currently owned by institutional investors and hedge funds.

About Century Therapeutics

(Get Free Report)

Century Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of allogeneic cell therapies for cancer. Utilizing induced pluripotent stem cell (iPSC) technology, the company engineers “off-the-shelf” natural killer (NK) and T cell candidates designed to target hematologic malignancies and solid tumors. By harnessing iPSC-derived immune cells, Century aims to overcome challenges associated with patient-derived therapies, such as manufacturing variability and treatment delays.

The company's proprietary platform integrates gene editing, synthetic biology and scalable cell expansion processes to generate a pipeline of product candidates.

Read More

• Five stocks we like better than Century Therapeutics
• The “secret weapon” behind Microsoft, Meta, Amazon, and Google
• A personal warning from Martin Weiss (Please read)
• Elon Musk: This Could Turn $100 into $100,000
• The Iran War Just Broke the Gold Market
• Iran isn't the real war

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Century Therapeutics Right Now?

Before you consider Century Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Century Therapeutics wasn't on the list.

While Century Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here